About Us

Our mission is to eradicate canine cancer, improve the quality of life for canine patients, and give new hope to pet parents.

What We Do

Currently, cancer care for dogs lags behind human cancer care by about 20 years. But, from a biological and molecular standpoint, canine cancer is not so different from human cancer. FidoCure uses genomic testing to deduce what therapies may be most effective to treat your dog’s specific type of cancer. From there, precision medicine can be prescribed by your vet and administered in the comfort of your home.

Our goal is to improve the outcome for canine cancer patients. We are the first and only company to offer the information needed to work with your veterinarian on targeted medicines for dogs with cancer.

Our Story

Behind the founding of the One Health Company, the world’s first canine cancer care organization, are two very human stories, both rooted in cancer…

Ben Lewis is no stranger to the world of clinical trials. As a former Olympic team kayaker, he had access to cutting-edge experimental care focused on treating serious injuries. When his dog was diagnosed with cancer, the chance to enroll in a clinical trial for canine cancer treatment arose. Lewis seized the opportunity and his dog outlived his prognosis, cancer-free.

Christina Lopes, on the other hand, served as a caretaker for her father when he was diagnosed with terminal lung cancer. Her experience navigating this complex illness, combined with Lewis’ journey through clinical testing, provided the perfect platform on which to build One Health.

Together, they co-founded the One Health Company to offer cutting edge diagnostics and access to targeted therapies for dogs. “One Health” is a term vets use to refer to the integrative efforts of multiple disciplines working to attain optimal health for people and animals.

Our Medical & Veterinary Advisors

We have assembled a board of medical and veterinary advisors including multidisciplinary thinkers in the areas of canine and human oncology. They boldly use all of our resources to positively impact the outcome for dogs with cancer. Our vets have treated thousands of dogs over the past 30 years and work closely with our growing network of forward-thinking veterinarians throughout the US.

Cheryl London DVM, PhD, ACVIM (Oncology)

Associate Dean for Research and Graduate Education Anne Engen and Dusty Professorship in Comparative Oncology Tufts University Graduate School of Biomedical Sciences Cummings School of Veterinary Medicine at Tufts University

Dr. Cheryl London, DVM, PhD, ACVIM (Oncology) is a Research Professor at Cummings School of Veterinary Medicine at Tufts University and the Molecular Oncology Research Institute at Tufts Medical Center. She has an active laboratory research program centered on comparative and translational oncology and is involved in the training of graduate students and postdoctoral fellows. She has recently joined the Clinical Trials Office at Cummings School to expand operations and enhance capacity and breadth of trials performed in client-owned animals.
Dr. London is also an Associate Faculty Professor at the Ohio State University College of Veterinary Medicine (OSU CVM) where she remains Director of the Clinical Trials Office at the CVM and Director of Translational Therapeutics at the Center for Clinical and Translational Sciences, OSU College of Medicine. Prior to her time at OSU, she was an Assistant Professor in the Department of Surgical and Radiological Sciences at the University of California, Davis.
Dr. London earned her Doctor of Veterinary Medicine at Cummings School, completed her residency in medical oncology at the University of Wisconsin-Madison and received her PhD in immunology at Harvard University, where she was also a postdoctoral fellow in the Department of Pathology.
Dr. London’s expanded bio
Follow Tufts Vet on Twitter

How dogs are teaching researchers new tricks for treating cancer by Sarah DeWeerdt, Nature

How Are Dogs Helping Us Cure Cancer in People? by Elaine K. Howley, U.S. News

Nicola Mason B.Vet.Med, PhD, ACVIM (SAIM)

Professor of Medicine & Pathobiology The Paul A. James and Charles A. Gilmore Endowed Chair Professorship within the Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania School of Veterinary Medicine

Dr. Mason’s lab focuses on developing novel approaches to generate functional, tumor-specific cytotoxic T lymphocytes. One approach involves active immunization using whole tumor RNA loaded CD40 activated B cells, aimed at activating tumor specific T cells in vivo. A second approach involves the passive adoptive transfer of genetically modified autologous T cells that are capable of MHC-independent tumor antigen recognition and activation/effector function in the absence of co-stimulatory ligands.
A second related focus of Dr. Mason’s lab is to identify novel tumor-associated antigens and to develop single-chain Fragment variable targeting systems that can be used alone or in concert with cell based therapies to target spontaneous occurring tumors. Through innovative clinical trials in canine cancer patients, the lab is working in concert with clinical oncologists to evaluate the safety and efficacy of both active immunization and passive adoptive transfer of genetically modified T cells in the treatment of spontaneously occurring cancer.
Dr. Mason’s expanded bio
Follow Penn Vet on Twitter

New tricks in canine cancer research may improve treatments for humans, too By Laurie McGinley, The Washington Post

Ravi Tolwani, DVM, PhD

Research Associate Professor and Associate Vice President Comparative Bioscience Center (CBC), the CRISPR and Genome Editing Center, and the Transgenic and Reproductive Technology Center at The Rockefeller University

Dr. Ravi Tolwani oversees the Gene Targeting Resource Center and Transgenic Services Laboratory of the Comparative Bioscience Center (CBC). The CBC provides expertise in animal models, research design and methodology, generation and evaluation of genetically engineered mouse models, and other collaborative efforts. It also provides training to Rockefeller investigators.
Dr. Tolwani holds a Doctor of Veterinary Medicine from Auburn University. After two years in private practice in Nashville, Tennessee, he turned to research, completing a Ph.D. in cellular and molecular pathology, and a postdoc fellowship in laboratory animal/comparative medicine at the University of Alabama. For his research, he developed a mouse model to study a common illness in humans associated with an enzyme deficiency in fat metabolism. Tolwani later earned an M.Sx. degree in management from the Stanford Graduate School of Business.
Dr. Ravi Tolwani Tolwani joined Rockefeller in 2007. From 1994 to 2007, he served on the faculty of the Stanford University School of Medicine, where his laboratory focused on understanding the molecular mechanisms of brain plasticity.
Dr. Tolwani’s expanded bio
Follow Dr. Tolwani on Twitter

Corrie Painter, Ph.D.

Associate Director of Operations and Scientific Outreach for the Broad Cancer Program, Associate Director of Count Me In Broad Institute of MIT and Harvard

Corrie Painter is the Deputy Director of Count Me In and is a research scientist at the Broad Institute of MIT and Harvard. A trained cancer researcher with a Ph.D. in biochemistry, she completed her postdoctoral work in cancer immunology, focused on melanoma. In 2010, Painter was diagnosed with breast angiosarcoma. She has combined her cancer advocacy and scientific background to engage with patients in order to build and carry out patient-partnered genomics studies such as the Metastatic Breast Cancer Project (MBCproject.org). She is also the co-founder of Angiosarcoma Awareness Inc.
Dr. Painter’s expanded bio
Follow Dr. Painter on Twitter

Elinor Karlsson, Ph.D.

Associate Professor, Program in Bioinformatics and Integrative Biology, and Program in Molecular Medicine, UMass Chan Medical School Director, Vertebrate Genomics Group, Broad Institute of MIT and Harvard Rice University, Boston University, Harvard University

Dr. Karlsson is an Associate Professor, Program in Bioinformatics and Integrative Biology, and Program in Molecular Medicine, UMass Chan Medical School. She is also the director of the Vertebrate Genomics Group at the Broad Institute of MIT and Harvard. Dr. Karlsson is excited by the potential for using our own evolutionary history to understand how the human genome works, and how that knowledge can lead to advances in healthcare.
Karlsson has a special interest in diseases shared between humans and dogs. She leads the citizen science-driven Darwin’s Dogs project, which invites all dog owners to participate directly in research exploring the genetic basis of dog behavior, as well as diseases such as OCD and cancer.
Karlsson’s current projects include the Zoonomia Project, an international effort led by the Vertebrate Genomics group at the Broad to compare hundreds of different mammalian genomes and identify critically important segments of DNA.
Dr. Karlsson’s expanded bio
Follow Dr. Karlsson on Twitter

Dr. J. Leonard “Len” Lichtenfeld, MD, MACP

Formerly: Deputy Chief Medical Officer, American Cancer Society Interim Chief Medical and Scientific Officer, American Cancer Society Co-leader nationwide response team for the coronavirus pandemic, American Cancer Society Leader, Cancer Control Science Department, American Cancer Society

Our Team

Our seasoned management team brings a diversity of experience to the organization from the areas of business, finance, advertising, and barking at friendly passers-by.

Christina Lopes

MA Founder & CEO

Benjamin Lewis


Dr. Gerald Post

DVM · MEM · DACVIM Chief Medical Officer

Chase Schwalbach

Chief Product Officer

Garret Harvey

VMD Head of Medical Affairs

Lindsay Lambert

Director of Clinical Operations

Dr. Michelle White

DVM · PhD Head of Science

Lucas Rodrigues

DVM, MS, PhD Head of Veterinary Research

Ben Toussant

JD Chief of Staff & Director of Strategic Operations

Aubrey Miller

Clinical Operations Associate

Abigail “Abby” Hull

CVT, VTS (ECC) Clinical Operations Associate